Cite
APA Citation
Lin, H., Ostrowitzki, S., Sink, K. M., Millar, L., Warren, F., Smith, J., Schneider, A., Fuji, R. N., Quartino, A., Mackey, H., Rabbia, M. A., Yule, S., Fontoura, P., & Doody, R. (n.d.). o1‐02‐04: BASELINE CHARACTERICS FROM A PHASE 3 TRIAL OF CRENEZUMAB IN PRODROMAL TO MILD ALZHEIMER'S DISEASE (CREAD). Alzheimer's & dementia, 14, P217. http://access.bl.uk/ark:/81055/vdc_100103406656.0x00001b